Purine and pyrimidine metabolism regulatory gene signature predicts prognosis and immunotherapy efficiency in breast cancer

Author:

Chang Lidan1,Cui Hanxiao1,Ren Xueting1,Dai Luyao1,Zhai Zhen1,Xiao Zhengtao,Wu Hao,Kang Huafeng1,Ma Xiaobin1

Affiliation:

1. The Second Affiliated Hospital of Xi’an Jiaotong University

Abstract

Abstract BACKGROUND Breast cancer (BC) is a heterogeneous disease with diverse molecular features and outcomes. Purine and pyrimidine (PP) metabolism provide sufficient nucleotides for tumor growth. Thus, the relationship between PP metabolism and BC needs a thorough exploration.METHODS Based on the 115 PP genes and BC multi-omics data, we performed consensus clustering and functional enrichment analyses to explore the biological characteristic. After the LASSO regression and multi-Cox regression analyses, a PP gene-related signature was developed. Moreover, data from the GSE45255, GSE21653, and GSE118389 cohorts, analyses included immunophenoscore (IPS) and single-cell RNA sequencing were employed to validate the predictability. Additionally, drug sensitivity and a comprehensive nomogram were explored for clinical practice.RESULTS PP genes were predominantly enriched in pathways related to immune stimulation, tumor aggressiveness, and EMT development. We identified three BC subtypes that possess different outcomes and immunological characteristics. We constructed an eleven-gene signature (SHCBP1, SSBP2, EIF4EBP1, FHL5, ACTL8, KLF9, IGKC, SEMA3B, CXCL1, CSTA, and IGLL5) that can be effectively for risk stratification, and was positively correlated with most T cell exhaustion-related genes (P < 0.05). The low-risk group possessed a better tumor microenvironment (P < 0.001), a higher expression level of immune checkpoint genes (P < 0.05), and showed immunotherapy benefits (P < 0.05). In addition, immune infiltrating cells demonstrated a characteristic distribution between the different risk groups (P < 0.05). Notably, patients with low-risk scores showed higher sensitivity to targeted drugs (veliparib, olaparib, and palbociclib), as well (P < 0.001).CONCLUSION PP metabolism regulatory gene signature suggests that patients assessed as low-risk have a better prognosis, immune microenvironment, and immunotherapy responses. It also inspired the exploration of biomarkers and provided novel strategies for clinical practice.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3